How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans
CEO Vohra Talks Strategy With Scrip
Executive Summary
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.
You may also be interested in...
Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
More Interest In Speculated Cipla Stake Sale: Portfolio, Cultural Fit Will Matter
After PEs, Torrent Pharma is speculated to be in the fray for a stake in Cipla. Experts weigh in on the contours of the product and cultural alignment of the two firms, should things move forward and also whether other Indian players could take a shot at the 'once in a lifetime opportunity'.